Is the easier way ever the better way?

Journal of Clinical Oncology

Volumn 29, Issue 31, 2011, Pages 4073-4075

  Chi, Dennis S ^a   Bristow, Robert E ^b   Armstrong, Deborah K ^c   Karlan, Beth Y ^d  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOTOXIC AGENT; PLATINUM DERIVATIVE;

ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CYTOREDUCTIVE SURGERY; DRUG EFFICACY; HUMAN; NOTE; OVARIECTOMY; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURVIVAL RATE; SURVIVAL TIME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANADA; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; EUROPE; FEMALE; GYNECOLOGY; HUMANS; MEDICAL ONCOLOGY; NEOADJUVANT THERAPY; OVARIAN NEOPLASMS; PLATINUM COMPOUNDS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS; SURVIVAL RATE; UNITED STATES;

EID: 80755181115     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.35.9935     Document Type: Note

References (18)

1. Griffiths CT: Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr 42:101-104, 1975
2. Bristow RE, Tomacruz RS, Armstrong DK, et al.: Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis. J Clin Oncol 20:1248-1259, 2002
3. Eisenhauer EL, Abu-Rustum NR, Sonoda Y, et al.: The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. Gynecol Oncol 103:1083-1090, 2006
4. Ozols RF, Bundy BN, Greer BE, et al.: Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 21:3194-3200, 2003
5. Armstrong DK, Bundy B, Wenzel L, et al.: Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354:34-43, 2006
6. Burger RA, Sill MW, Monk BJ, et al.: Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic Oncology Group Study. J Clin Oncol 25:5165-5171, 2007
7. du Bois A, Reuss A, Pujade-Lauraine E, et al.: Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: By the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer 115:1234-1244, 2009
8. Hoskins WJ, Bundy BN, Thigpen JT, et al.: The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: A Gynecologic Oncology Group study. Gynecol Oncol 47:159-166, 1992
9. Aletti GD, Dowdy SC, Gostout BS, et al.: Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet Gynecol 107:77-85, 2006
10. Chi DS, Eisenhauer EL, Zivanovic O, et al.: Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol 114:26-31, 2009
11. Crawford SC, Vasey PA, Paul J, et al.: Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 Trial. J Clin Oncol 23:8802-8811, 2005
12. Hou JY, Kelly MG, Yu H, et al.: Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease. Gynecol Oncol 105:211-217, 2007
13. Zivanovic O, Eisenhauer EL, Zhou Q, et al.: The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal cancer. Gynecol Oncol 108:287-292, 2008
14. Chi DS, Eisenhauer EL, Lang J, et al.: What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma? Gynecol Oncol 103:559-564, 2006
15. Vergote I, Tropé CG, Amant F, et al.: Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 363:943-953, 2010
16. Chi DS, Zivanovic O, Levinson KL, et al.: The incidence of major surgical complications after the performance of extensive upper abdominal surgical procedures during primary cytoreduction of advanced ovarian, tubal, and peritoneal carcinomas. Gynecol Oncol 119:38-42, 2010
17. Bristow RE, Chi DS: Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: A meta-analysis. Gynecol Oncol 103:1070-1076, 2006
18. Bristow RE, Eisenhauer EL, Santillan A, et al.: Delaying the primary surgical effort for advanced ovarian cancer: A systematic review of neoadjuvant chemotherapy and interval cytoreduction. Gynecol Oncol 104:480-490, 2007